{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.67","upperLimit":"90.39","value":"78.21"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"}],"units":"Participants"}],"description":"Platelet response was defined as a platelet count of ≥ 50 x 10⁹/L with no rescue medication use in the past 4 weeks.\n\nMonthly platelet response was calculated based on the median platelet count during each month. For each participant, the percentage of time with platelet response was calculated as the number of months a platelet response was observed divided by the total number of months response was assessed.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years. The starting dose was 1 µg/kg titrated in 1 µg/kg increments up to a maximum of 10 µg/kg to reach a target platelet count ≥ 50 x 10⁹/L.","id":"OG000","title":"Romiplostim"}],"paramType":"MEDIAN","populationDescription":"Efficacy analysis set","reportingStatus":"POSTED","timeFrame":"From week 2 to the end of the treatment period, 36 months","title":"Percentage of Time With a Platelet Response During the Overall Treatment Period","type":"SECONDARY","unitOfMeasure":"percentage of time"}